Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock Has Consensus Target Price of $42.12

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has been assigned an average recommendation of “Moderate Buy” from the ten brokerages that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $42.12.

A number of equities analysts have recently commented on AGIO shares. JPMorgan Chase & Co. lifted their target price on Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. Citigroup increased their price target on Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a “buy” rating in a report on Friday, July 31st. TD Cowen upgraded Agios Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 24th. Bank of America lifted their price objective on shares of Agios Pharmaceuticals from $46.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, September 21st. Finally, Truist Financial cut their price objective on shares of Agios Pharmaceuticals from $37.00 to $35.00 and set a “buy” rating on the stock in a research report on Friday, November 6th.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ AGIO opened at $31.76 on Wednesday. The business’s 50 day moving average is $33.19 and its two-hundred day moving average is $31.80. Agios Pharmaceuticals has a 1-year low of $22.24 and a 1-year high of $46.00. The stock has a market capitalization of $1.90 billion, a P/E ratio of -5.03 and a beta of 0.66.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.24) by $0.15. The business had revenue of $55.39 million for the quarter, compared to the consensus estimate of $51.65 million. Agios Pharmaceuticals had a negative return on equity of 34.63% and a negative net margin of 264.76%. As a group, equities research analysts anticipate that Agios Pharmaceuticals will post -5.75 earnings per share for the current fiscal year.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, insider Sarah Gheuens sold 7,866 shares of the firm’s stock in a transaction dated Monday, October 26th. The shares were sold at an average price of $37.69, for a total value of $296,469.54. Following the completion of the sale, the insider owned 54,645 shares in the company, valued at approximately $2,059,570.05. This trade represents a 12.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 9,855 shares of company stock valued at $371,112 over the last quarter. Corporate insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Nykredit A S purchased a new stake in Agios Pharmaceuticals in the 2nd quarter worth about $26,000. Three Bridge Wealth Advisors LLC bought a new stake in Agios Pharmaceuticals in the third quarter worth about $27,000. Quantbot Technologies LP bought a new stake in Agios Pharmaceuticals in the second quarter worth about $43,000. Integrated Wealth Concepts LLC purchased a new position in shares of Agios Pharmaceuticals during the second quarter valued at approximately $47,000. Finally, Allworth Financial LP purchased a new position in shares of Agios Pharmaceuticals during the second quarter valued at approximately $73,000.

Key Headlines Impacting Agios Pharmaceuticals

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts for Agios across 2026–2030, including a move to projected profitability in 2030 of $2.01 per share from $0.72. The firm reiterated its Buy rating and $62 price target. Agios Pharmaceuticals analyst estimates
• Positive Sentiment: Bank of America Securities maintained its Buy rating, while another report said Agios’ price target was raised to $62. These endorsements add to the favorable analyst tone. Bank of America Securities maintains Buy rating Agios price target raised to $62
• Neutral Sentiment: A short-interest report says the figure was 0 shares, despite describing a “significant increase,” and gives a zero-day short-interest ratio. The conflicting wording makes this difficult to interpret as a reliable trading signal.
• Negative Sentiment: Truist Financial reportedly trimmed its price target for AGIO, a counterpoint to the more bullish analyst updates; the supplied headline does not state the revised target. Truist Financial trims Agios price target

About Agios Pharmaceuticals

Agios Pharmaceuticals is a biopharmaceutical company focused on developing medicines for rare genetic diseases, particularly blood disorders. Based in Cambridge, Massachusetts, the company applies research into cellular metabolism to identify potential treatments. Its marketed medicine, PYRUKYND (mitapivat), is approved in the United States to treat adults with pyruvate kinase deficiency, a rare inherited disorder that can cause anemia. Agios also develops therapies for other rare diseases, including additional blood disorders.